TY - JOUR
T1 - Role of LH in ovarian stimulation: Considerations
AU - Griesinger, Georg
AU - Diedrich, Klaus
PY - 2006/4
Y1 - 2006/4
N2 - The role of LH in ovarian stimulation continues to be controversial. Most observational studies on both gonadotrophin-releasing hormone (GnRH) agonist and GnRH antagonist protocols failed to show an effect on ongoing pregnancy likelihood of punctually measured 'low' or 'high' endogenous LH concentrations during ovarian stimulation. As yet, it is still unknown whether individual patients with strongly suppressed levels of immunoreactive LH would actually benefit from additional LH administration. This can only be explored by means of interventional trials. Most trials on LH supplementation in general populations in both GnRH agonist and GnRH antagonist protocols have not found a benefit of LH supplementation, although it has been indicated that some subgroups, such as older age patients, or patients with a low ovarian response might benefit from LH. These concepts need to be explored further before recommendations can be given as to in who, in what protocol, at what time point and in what doses LH should be supplemented.
AB - The role of LH in ovarian stimulation continues to be controversial. Most observational studies on both gonadotrophin-releasing hormone (GnRH) agonist and GnRH antagonist protocols failed to show an effect on ongoing pregnancy likelihood of punctually measured 'low' or 'high' endogenous LH concentrations during ovarian stimulation. As yet, it is still unknown whether individual patients with strongly suppressed levels of immunoreactive LH would actually benefit from additional LH administration. This can only be explored by means of interventional trials. Most trials on LH supplementation in general populations in both GnRH agonist and GnRH antagonist protocols have not found a benefit of LH supplementation, although it has been indicated that some subgroups, such as older age patients, or patients with a low ovarian response might benefit from LH. These concepts need to be explored further before recommendations can be given as to in who, in what protocol, at what time point and in what doses LH should be supplemented.
UR - http://www.scopus.com/inward/record.url?scp=33645770238&partnerID=8YFLogxK
U2 - 10.1016/S1472-6483(10)61990-6
DO - 10.1016/S1472-6483(10)61990-6
M3 - Comments/Debates
C2 - 16740210
AN - SCOPUS:33645770238
SN - 1472-6483
VL - 12
SP - 404
EP - 406
JO - Reproductive BioMedicine Online
JF - Reproductive BioMedicine Online
IS - 4
M1 - 2270
ER -